A new blueprint for active immunotherapy
Using our Ambifect® Fc-fusion platform, Twilight creates immunotherapies that trigger targeted, long-lasting antibody responses against chronic disease.
Founded by experts in neurology, immunology, and biotech
1
Identify
Map the unique immune response to pathogens
2
Optimize
Identify immunity gaps and  vaccine targets
3
Design Vaccine
Design a personalized vaccine that delivers lasting immunity
The result
A scalable platform to create therapies that are:
Effective
The same life-saving impact of mAB treatments
Affordable
~$0.50 manufacturing cost per dose
Personalized
Targets multiple proteins and epitopes for a stronger immune response
long-lasting
Triggers immunity through multiple activation mechanisms
Easy to store and transport
Stable for >12 months at room temperature
Less invasive
The same life-saving impact of mAB treatments
The science works.
We’ve proven it at scale.
Our Fc-platform vaccine completed Phase III clinical trials for COVID-19 demonstrating strong, durable immunity across thousands of patients
1,782
Patients
90%+
Antibody response
<$0.40
Manufacturing cost
Let's talk
We’re looking to partner with those who want to shape the future of immunotherapy.
Contact us